You are here

  • Home
  • Archive
  • Volume 1, Issue Suppl 1
  • A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared with the RNActive technology results in distinctly longer survival than predicted by the Halabi Nomogram which correlates with the induction of antigen-specific immune responses

Article metrics

Article menu

Download PDFPDF

Poster Presentation
A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared with the RNActive technology results in distinctly longer survival than predicted by the Halabi Nomogram which correlates with the induction of antigen-specific immune responses

 

Online download statistics by month:

Online download statistics by month: December 2019 to August 2024

AbstractFullPdf
Dec 2019020
Jan 2020031
Feb 2020031
Apr 2020011
May 2020060
Jun 20200620
Jul 2020040
Aug 2020010
Sep 2020090
Nov 2020021
Dec 2020063
Jan 2021070
Feb 2021021
Mar 2021032
Apr 2021041
May 2021035
Jun 2021050
Jul 2021030
Sep 2021020
Oct 2021041
Nov 2021075
Dec 2021081
Jan 2022070
Feb 2022060
Mar 2022031
Apr 20220105
May 20220253
Jun 20220151
Jul 20220155
Aug 2022091
Sep 20220140
Oct 20220156
Nov 20220138
Dec 20220123
Jan 2023080
Feb 20230240
Mar 2023092
Apr 2023064
May 2023030
Jun 20230362
Jul 2023065
Aug 2023041
Sep 2023061
Oct 2023043
Nov 20230121
Dec 2023031
Jan 2024071
Feb 20240663
Mar 202405116
Apr 202401214
May 2024095
Jun 2024020
Jul 20240132
Aug 2024010
Total0527217